Who
William John Sibold
President and CEO
Company insider
Files Form 4 as: President and CEO, Madrigal Pharmaceuticals; Other, Avanir Pharmaceuticals.
In numbers
- Trades disclosed
- 99
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $28.0M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 3 May 2011
- Last trade
- 11 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $32K60 at $533.09 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $57K106 at $534.06 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $117K218 at $535.94 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $86K160 at $537.62 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $371K687 at $540.59 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $199K368 at $541.64 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $652K1,202 at $542.60 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $837K1,539 at $544.02 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $415K761 at $544.83 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $66K120 at $546.38 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $32K60 at $533.09 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $57K106 at $534.06 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $117K218 at $535.94 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $86K160 at $537.62 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $371K687 at $540.59 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $199K368 at $541.64 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $652K1,202 at $542.60 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $837K1,539 at $544.02 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $415K761 at $544.83 | filing |
| 11 Sep 2026filed 11 Sep 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $66K120 at $546.38 | filing |
News
Head-To-Head Contrast: Zai Lab (NASDAQ:ZLAB) versus Madrigal Pharmaceuticals (NASDAQ:MDGL)MDGL · dailypolitical.com · 25 Oct 2026Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY)MDGL · themarketsdaily.com · 20 Oct 2026Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026MDGL · manilatimes.net · 20 Oct 2026
0 headlines in the last 90 days name William John Sibold; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.